KKR Backs Avisena’s Bid to Double Capacity as Capital Flows Into Malaysian Hospitals

Global private equity firm KKR has agreed to buy a minority stake in Avisena Healthcare, backing a plan to more than double the Malaysian hospital operator’s bed capacity to nearly 600 by 2029. Although the strategic transaction will focus on an aggressive multi-year initiative, both parties have left the final valuation and the critical primary-secondary funding split closely guarded. The harder question is how much fresh institutional liquidity will actually reach the physical operating business.

The companies announced the deal on September 4, but neither side disclosed the stake size, investment value or security structure. Reuters reported in August that KKR was the preferred bidder for a 20-25% holding worth RM300-400 Mn, implying a valuation of about RM1.5 Bn ($368 Mn) for Avisena. KKR declined to confirm those figures. 

SJ Lim, the KKR managing director leading the deal, said the global private equity giant is “honored and excited to be working with Avisena’s shareholders”. Avisena’s group chief executive officer Elina Nadia Omar said she was “pleased to welcome KKR as an institutional investor”. 

Pre-Funded Expansion Meets an Opaque Capital Structure

Avisena’s expansion was well underway before KKR’s arrival. The company awarded a RM174.3 Mn construction contract for its Shah Alam project in May 2024 and acquired the land for its planned Cyberjaya hospital back in 2022. 

KKR and Avisena have not specified whether the investment consists of newly issued primary shares, a secondary purchase from existing shareholders, or a combination of both. This leaves open the critical question of how much of KKR’s capital will directly fund construction versus buying out current owners. 

One detail complicates the transaction profile. Lim also heads KKR’s Asia private credit business, which closed a $2.5 Bn fund in January 2026, targeting senior and unitranche lending, capital solutions and collateral-backed investments. 

Although this does not confirm that the current deal involves debt, KKR has described it strictly as a “minority investment” without naming the security class. Whether the fund injection comes via common equity, preferred shares, a convertible instrument or structured credit will dictate Avisena’s ultimate leverage profile.

From Founder Roots to Capital Market Asset

KKR’s entry brings institutional governance to a business still tightly controlled by its founder. Dato’ Dr Omar Abd Hamid built Avisena from a distressed, single-asset clinic acquired during the Asian financial crisis. 

Corporate registry filings and disclosures in the annual report of facilities management company UEM Edgenta—where Omar sits on the board—reveal that Avisena Holdings wholly owns Avisena Healthcare, and Oratis Healthcare controls this vehicle with a 54.85% stake. Omar owns 85.42% of Oratis, giving him an indirect economic interest of roughly 46.9% in Avisena Holdings before any post-transaction dilution.

As the two sides have not disclosed Avisena’s post-transaction ownership structure, it remains unclear whether existing shareholders are trimming their exposure, or what specific board seats and minority protections KKR has negotiated.

A Blueprint That Outpaces Its Sizable Roots

Avisena currently runs more than 250 licensed beds across Avisena Specialist Hospital and Avisena Specialist Hospital 2 in Shah Alam. Its 2025 sustainability report notes 254 operational beds, over 1,000 employees, 75 resident specialists and 44 clinical specialities and sub-specialities. 

The new Shah Alam tower will push capacity across the two existing hospitals to 418 beds. KKR and Avisena’s joint announcement puts the combined addition from that tower and the upcoming Cyberjaya hospital at more than 300 beds. This will scale total capacity to nearly 600 beds by 2029, although the companies did not disclose how the allocation splits between the two sites. 

Avisena is also moving beyond raw bed counts towards higher-yield medical acuity. In August, it rebranded its women’s and children’s facility as Avisena Specialist Hospital 2, adding 12 specialists and eight specialist services, including ENT, orthopaedics, general surgery and others. 

That pivot makes the expansion as much a test of clinical execution as it is of construction. Avisena must scale up its specialists, nursing staff, insurer relationships and bed utilisation rates to match its rapidly growing physical footprint. 

Why Malaysia’s Hospitals Are Flooded with Capital

Three distinct forces are drawing institutional money into the Malaysian healthcare sector. An ageing population is driving chronic disease and higher-acuity cases. Public hospital capacity has also failed to keep pace with demand, pushing middle-class and affluent patients to private beds. Finally, Malaysia has established itself as a regional medical tourism hub, drawing foreign patients at costs well below Singapore and Western nations. 

Malaysia’s ministry of health counted 212 licensed private hospitals with 18,779 beds at the end of 2023, the most recent year with verified published data. Avisena is small against that base, but its expansion represents a major scaling event for a founder-led operator heavily concentrated in the affluent Klang Valley market. 

Institutional appetite for the sector remains robust. In March, Sunway Healthcare, the hospital arm of Malaysian conglomerate Sunway Group, raised RM2.86 Bn in Malaysia’s largest IPO in nearly a decade, valuing the 1,805-bed operator at RM16.7 Bn and surging 28% on its trading debut.

Also, Bloomberg reported on September 2 that Asia OneHealthcare, a hospital group backed by the U.S. private equity firm TPG, had confidentially filed for a Kuala Lumpur IPO that could raise up to RM10 Bn, even as PE buyers continue to circle the business for a potential trade sale. 

The strategies diverge by maturity. Sunway is leveraging public markets to fund an active domestic expansion. TPG is weighing late-stage liquidity from a mature regional network. KKR, by contrast, is buying into a mid-sized, founder-led operator just before its most capital-intensive growth phase. 

The Payor Squeeze

Yet rising regional demand does not guarantee friction-free financial returns. Bank Negara Malaysia, the central bank, reported that medical payouts by life insurers and family takaful operators rose to RM6.5 Bn in the second half of 2025, up from RM5.7 Bn in the first half, driven by climbing hospital admissions. However, net underwriting losses widened to RM3.6 Bn over the same period, prompting regulators to design a standardised, voluntary medical protection framework intended to phase in premium increases. 

This macro shift relocates Avisena’s primary commercial risk from construction to operational utilisation. A larger footprint secures regional scale, but it also deepens exposure to an insurance sector currently absorbing steep losses. As insurers push back on treatment tariffs and demand more stringent proof of clinical outcomes before settling claims, how effectively Avisena navigates these payor disputes will matter far more than the strength of KKR’s balance sheet.